02851nam 22006013u 450 99633908930331620230721021218.01-282-09392-497866120939201-84692-610-6(CKB)1000000000747783(EBL)434064(OCoLC)666932718(SSID)ssj0000383582(PQKBManifestationID)12110796(PQKBTitleCode)TC0000383582(PQKBWorkID)10331848(PQKB)10553549(Au-PeEL)EBL434064(MiAaPQ)54807(EXLCZ)99100000000074778320130418d2009|||| u|| |engur|n|---|||||txtccrTherapeutic Strategies in Pulmonary Arterial Hypertension[electronic resource]1st ed.Oxford Atlas Medical Publishing Ltd20091 online resource (101 p.)Therapeutic StrategiesDescription based upon print version of record.1-84692-053-1 Contents; Editors and Contributors; Chapter 1: Imaging of the right heart and pulmonary circulation; Chapter 2: Exercise testing and haemodynamics; Chapter 3: Epidemiology of pulmonary arterial hypertension; Chapter 4: Current treatment of PAH: prostanoids, phosphodiesterase-5 inhibitors and stimulators of soluble guanylate cyclase; Chapter 5: The future treatment of pulmonary hypertension; Chapter 6: Endothelin receptor antagonists; Chapter 7: Gene and stem cell therapy in pulmonary arterial hypertension; Abbreviations; IndexPulmonary arterial hypertension (PAH) is a rare condition; yet this very rarity can be a disadvantage when it comes to treatment, making PAH difficult to diagnose, and resulting in suboptimal patient care. Furthermore, the global burden of PAH remains poorly understood and largely underestimated, as PAH commonly presents as a comorbidity with such conditions as systemic sclerosis, COPD, idiopathic pulmonary fibrosis and left-heart dysfunction. However, in recent years there has been significant investment in developing new therapies for PAH, and treatment for this previously neglected disease Therapeutic StrategiesHypertension, PulmonaryPulmonary arteryPulmonary hypertensionHypertension, Pulmonary.Pulmonary artery.Pulmonary hypertension.616.24Peacock A1001220Barberà J1001221AU-PeELAU-PeELAU-PeELBOOK996339089303316Therapeutic Strategies in Pulmonary Arterial Hypertension2298043UNISA